Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases

International Journal of Gynecological Cancer

Volumn 10, Issue 4, 2000, Pages 280-284

  McCluggage, W G ^a   Abdulkader, M ^b   Price, J H ^a,c   Kelehan, P ^d   Hamilton, S ^b   Beattie, J ^e   Al Nafussi, A ^b  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d NATIONAL MATERNITY HOSPITAL   (Ireland)

^e ST JOHN'S HOSPITAL   (United Kingdom)

Author keywords

Carcinosarcoma; Tamoxifen; Uterus

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; UTERUS;

EID: 0033818713     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.010004280.x     Document Type: Article

References (36)

1. Mesenchymal tumors of the uterus
2. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas
3. Uterine malignant mixed Mullerian tumor in a patient on long term tamoxifen therapy for breast cancer
4. Is there an association between long term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus?
5. Uterine carcinosarcoma in association with tamoxifen therapy
6. Uterine carcinosarcoma in association with tamoxifen therapy
7. Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer
8. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
9. Tamoxifen for early breast cancer: An overview of the randomised trials
10. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancer
11. Breast cancer trial stopped early
12. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
13. Biology and mode of action of pure antiestrogens
14. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice
15. Tamoxifen and the uterus and endometrium
16. Pathology of endometrium treated with tamoxifen
17. Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary: Carcinomatous cells are changeable to sarcomatous cells
18. Characteristics of cloned cells of mixed Mullerian tumor of the human uterus: Carcinoma cells showing myogenic differentiation in vitro
19. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal
20. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy
21. Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma
22. Sonographic characteristics of adenofibroma of the endometrium following tamoxifen therapy for breast cancer: Two case reports
23. Oestrogen use and survival in endometrial cancer
24. Endometrial carcinoma: Clinicopathologic comparison of cases in postmenopausal women receiving exogenous estrogens
25. On the age-dependent association between cancer of the breast and endometrium. A nationwide cohort study
26. Risk of endometrial cancer after tamoxifen treatment of breast cancer
27. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer
28. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features
29. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the national surgical adjuvant breast and bowel project (NSABP) B-14
30. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients
31. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen
32. Endometrial changes with chronic tamoxifen use
33. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients
34. Tumors of the endometrium
35. Adjuvant tamoxifen: How long before we know how long?